US equities |
SPCX $167.68 ▲+5.49% NVDA $236.58 ▲+1.12% MU $1,067.56 ▼-0.68% TSLA $378.72 ▲+2.19% MSFT $526.22 ▲+1.68% SNDK $1,710.65 ▼-0.54% INTC $117.14 ▼-1.84% META $744.86 ▲+2.30%
FinancialContent

Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

20.80 -1.12 (-5.11%)
Delayed Quote Updated: 12:49 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Nuvectis Pharma, Inc. - Common Stock

< Previous 1 2 3 Next >
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Recap: Nuvectis Pharma Q3 Earnings ↗
 
Via Benzinga
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Nuvectis (NVCT) Q2 Loss Widens 43% ↗
Via The Motley Fool
News headline image
Discover the top movers in Thursday's pre-market session. ↗
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nuvectis Pharma's NXP900: Could This Revolutionary Cancer "Inactivator" Transform Oncology Treatment?
Truffle Pigs Blog Highlights Potential Game-Changing Cancer Therapy with Unique Mechanism of Action 
Via News Direct
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug ↗
Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing. 
Via Benzinga
News headline image
S&P 500 Moves Lower; US Crude Oil Inventories Increase ↗
 
Via Benzinga
Topics Stocks
News headline image
Dow Falls Over 100 Points; US Producer Prices Rise In October ↗
 
Via Benzinga
Topics Stocks
News headline image
US Stocks Edge Lower; Cisco Earnings Top Views ↗
 
Via Benzinga
News headline image
From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B). 
Via News Direct
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge. 
Via News Direct
News headline image
Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment
Report spotlights Nuvectis Pharma's (NASDAQ: NVCT) NXP900 as a potential game-changer in NSCLC treatment, noting its unique mechanism targeting SRC/YES1 kinases and promising preclinical data 
Via News Direct
News headline image
Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data
Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data 
Via News Direct
News headline image
7 Penny Biotech Stocks to Triple Your Investment ↗
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. 
Via InvestorPlace
News headline image
NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024 ↗
NVCT stock results show that Nuvectis Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
5 Healthcare Stocks to Buy for 2024 ↗
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023 ↗
NVCT stock results show that Nuvectis Pharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 Next >